Clinical Trial Update: Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial examining a triple-drug regimen (adebrelimab, apatinib, and etoposide) for HER2-negative breast cancer with brain metastases; recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Apatinib (apatinib)
• Etoposide (Etoposide)

Snippet

Sponsor: Beijing 302 Hospital | Conditions: HER2-negative Breast Cancer Brain Metastases | Phase 2 | Status: RECRUITING